The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Mario Luca Morieri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Padova, Padua, Italy. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Diabetic Nephropathies. Die Arbeit nennt 37 Literaturangaben. Gefördert von: University of Padova, Università degli Studi di Padova.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To determine whether the sequence of initiation between sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) influences kidney outcomes in people with type 2 diabetes (T2D) receiving these therapies in association. Materials and methods We retrospectively included adults with T2D treated with both a SGLT2i and a GLP‐1RA, stratified by treatment sequence: SGLT2i followed by GLP‐1RA or GLP‐1RA followed by SGLT2i. The primary endpoint was the change in estimated glomerular filtration rate (eGFR) from initiation of the first drug. Analyses used mixed models for repeated measures adjusted with inverse probability of treatment weighting (IPTW) and confirmed by propensity score matching (PSM).
Results
Among 565 participants (mean age 64 years, 29% women, diabetes duration 14 years, baseline eGFR 80 mL/min/1.73 m 2 ), 210 initiated SGLT2i first and 355 GLP‐1RA first. Over a median 4.3‐year follow‐up, eGFR declined more slowly in the SG group than in the GS group (adjusted difference 0.80 mL/min/1.73 m 2 per year; 95% CI 0.23–1.37; p = 0.006); this effect was more evident in patients with CKD at baseline. PSM analyses yielded consistent results. Changes in urine albumin‐to‐creatinine ratio, HbA1c, and body weight were similar between groups.
Conclusions
In people with T2D receiving combination therapy, initiating treatment with a SGLT2i was associated with greater long‐term preservation of kidney function compared with starting with a GLP‐1RA. Early SGLT2i use may confer better renal protection even when GLP‐1RA intensification is subsequently required, confirming SGLT2i as a foundational therapy for preventing the decline in renal function in T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Padova, Padua, Italy.
- Unit of Internal Medicine 3, University Hospital of Padova, Padua, Italy.
- Unit of Metabolic Diseases, University Hospital of Padova, Padua, Italy.
- Veneto Institute of Molecular Medicine, Padua, Italy.
ORCID-Profile: Paola Fioretto, Gian Paolo Fadini
Förderung
- University of Padova
- Università degli Studi di Padova
Zitieren
APA
Morieri, M. L., Vedovato, M., Bonora, B. M., Fioretto, P., & Fadini, G. P. (2026). The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70445
Vancouver
Morieri ML, Vedovato M, Bonora BM, Fioretto P, Fadini GP. The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70445
BibTeX
@article{Morieri2026,
author = {Morieri, Mario Luca and Vedovato, Monica and Bonora, Benedetta Maria and Fioretto, Paola and Fadini, Gian Paolo},
title = {The importance of treatment sequencing with SGLT2 inhibitors and GLP ‐1 receptor agonists combination for kidney function preservation in type 2 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70445}
}
EUVIMED